This course is part of the P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 curriculum.
elderly woman grimacing holding the back of her neck

This course is part of the P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 curriculum.

Interactive Learning

1.25 CME Credit

Part 2: Reducing Risks with Opioid Use
This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

Reducing Risks with Opioid Use is Part 2 of the 3-part curriculum, P.A.C.T. Practical Approaches to Comprehensive Treatment of Pain, which examines the full spectrum of pain management options available to clinicians, including the safe and effective use of opioids. 

In Part 2, you will learn about different opioids available for pain management and best practices for reducing risk associated with opioid use. You will also learn how to recognize signs of opioid use disorder and distinguish it from tolerance and physical dependence, and how to recognize and treat opioid overdose in your patients. 

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).

Each activity will cover various state-specific content and guidelines, also available for download.

Learners must complete three parts; Part 1: Assessing Pain and Initiating Non-Opioid Pain Management, Part 2: Reducing Risks with Opioid Use, and Part 3: Approaches to Opioid Treatment and Counseling Patients, in order to be a fully FDA Blueprint compliant completer

 

Begin

CME Information

1.25 AMA PRA Category 1 Credits™, 1.25 ABIM MOC or 1.27 AANP, including 0.64 AANP Pharm

Release Date: 11/22/2024

Expiration Date: 10/31/2025

Topics

Faculty

Learning Objectives

  • Differentiate among tolerance, physical dependence, and manifestations of opioid use disorder
  • Recognize best practices to reduce the risks associated with prescription of opioid analgesics, including safe storage and disposal 
  • Anticipate and manage adverse effects of opioid use including signs of opioid overdose and the use of naloxone

 


State Licensure Requirements

This activity satisfies topic-specific CME/CE requirements (pain management, controlled substances, etc.) of many state licensing boards. Please check with your state’s licensing boards for specific requirements, and print this page as appropriate for documentation. For more information, visit https://www.pri-med.com/state/state-mandated

Alabama: This activity is approved for Controlled Substance Prescribing Practices, Recognizing Signs of Abuse or Misuse of Controlled Substances, or Prescribing for Pain Management by the Alabama Board of Medical Examiners & Medical Licensure Commission

Iowa: This activity is designed to satisfy requirements of ARNPs, for CE regarding the US Centers for Disease Control and Prevention Guideline for prescribing opioids for chronic pain. Please print this page as documentation, for submission with your CE certificate.

Kentucky: This activity is approved for Addiction Medicine by the Kentucky Board of Medical Licensure, ID# 0924-H4.0-PMI9a

New Mexico: This activity is approved for Continuing Education for the Prescribing of Controlled Substances by the New Mexico Medical Board.

Texas: This activity is approved for Pain Management and Prescription of Opioids requirements from the Texas Medical Board/Board of Nursing, as well as Medical Ethics and/or Professional Responsibility.

Utah: This activity is approved to fulfill the Utah Requirement under Utah Code 58-37-6.5 by the Utah Division of Professional Licensing

This activity satisfies training requirements for the MATE Act, which requires all DEA-registered practitioners to complete 8 hours of CME/CE credit on opioid or other substance use disorders. 

Faculty

Oscar A. de Leon-Casasola, MD

Professor of Anesthesiology and Medicine
Senior Vice-Chair
School of Medicine and Biomedical Sciences
University at Buffalo
Chief, Pain Medicine and Professor of Oncology
Roswell Park Cancer Institute
Buffalo, New York

 
Learn More

Charles E. Argoff, MD, FABPM

Vice Chair
Professor of Neurology and Urology
Albany Medical College
Director, Comprehensive Pain Center
Director, Pain Management Fellowship
Albany Medical Center
Albany, New York
 
Learn More

Katherine E. Galluzzi, DO, CMD, FACOFP

Professor and Chair
Department of Geriatric and Palliative Medicine
Director, Comprehensive Care
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania 

 
Learn More

Disclosures

The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.

Charles E. Argoff, MD, FABPM: Speaker: AbbVie, Averitas Pharma, Impel, Kowa Pharmaceuticals, Lilly, Lundbeck, Nevro, Scilex, Teva; Researcher: Abbvie; Consultant: Collegium, Nevro, Pain Scripts, Scilex, Tris, Vertex, Xgene Pharma; Stockholder: Pfizer and Trevana; Investigator: Lundbeck and Teva.

Katherine E. Galluzzi, DO, CMD, FACOFP: No relevant financial relationships disclosed.

Oscar A. de Leon-Casasola, MD: Consultant: Merck Pharmaceuticals, Vertex Pharmaceuticals.

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

 

CME Information

AMA PRA Category 1 Credits™

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Miller Medical Communications.Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

Accreditation Statement

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308.

 

Designation Statement

This activity is approved for 1.27 contact hour, which includes 0.64 hour of pharmacology. 

MOC Credit Information

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points and Patient Safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Pri-Med Institute reports completion information to ACCME on a monthly basis, in the first week of each month. Pri-Med Institute reports completion information to ACCME on a monthly basis, in the first week of each month.

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory,  P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) for the following ABMS Member Boards: 

Lifelong Learning CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Preventive Medicine
Psychiatry and Neurology
Radiology

 

MIPS

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

For guidance on how clinicians can attest to participation in a MIPS Improvement Activity, visit https://qpp.cms.gov/mips/improvement-activities

mips logo

Instructions for Obtaining Credit

Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 2 out of the 3 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen. For PAs, the NCCPA accepts for Category 1 CME credit activities designated for AMA PRA Category 1 Credit.

Commercial Supporter

Opioid Analgesic REMS Program Companies

Education Partner

Miller Medical Communications, LLC

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.

Part 2: Reducing Risks with Opioid Use

Begin